Skip to main content
. 2019 Aug 1;10(4):699–710. doi: 10.14336/AD.2018.1128

Figure 4. The effect of lincRNA-p21 on senescence of human vascular SMCs.

Figure 4.

(A) The expression of lincRNA-p21 in human vascular smooth muscle cells stimulated by different doses of IgE. (B) The expression of lincRNA-p21 in human vascular smooth muscle cells stimulated by 10 μg/ml IgE at different time. (C) Detection of lincRNA-p21 expression in HSMC after transfectioned with lincRNA-p21 siRNA. (D) Representative images of HSMC β-galactosidase staining of control, IgE, si-lincRNAp21 and si-lincRNA-p21+IgE treatment groups. Scale bar: 100μm. (E) The senescent cell counts of HSMC after control, IgE, si-lincRNA-p21 or si-lincRNA-p21+IgE treatment. (F) PCR detection of p21 and p53 expression in HSMCs treated with IgE and si-lincRNA-p21. (G) Statistical analysis of p21 and p53 in HSMC treated with IgE and si-lincRNA-p21. (H) Western blot analysis of p21 and p53 in HSMC after IgE and si-lincRNA-p21 treatments. (I) Statistical analysis on the relative intensities of p21 and p53 protein expression in HSMC treated with IgE and si-lincRNA-p21. Data information: Data are presented as mean ± SEM. *P < 0.05; **P<0.01.